Latest TroVax Stories

- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility - TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed the planned patient enrollment in its U.S. Phase I clinical trial evaluating bavituximab as monotherapy in patients with...

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer - - Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment - - Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could...

A majority of patients with advanced colorectal cancer that has spread to other organs may skip surgery and begin chemotherapy, U.S. researchers say. Lead author Philip Paty says the conventional approach to treating stage IV level of colon cancer had been surgery immediately following diagnosis, typically followed by chemotherapy three to six weeks later. Paty and a multidisciplinary team looked at 233 patients with metastatic colorectal cancer treated at Memorial Sloan-Kettering Cancer...

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and TUSTIN, Calif., June 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that preliminary results from a Phase II trial of its lead anti-phosphatidylserine antibody...

GAITHERSBURG, Md., June 1 /PRNewswire-FirstCall/ -- Overall survival data in locally advanced pancreatic cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) were presented yesterday at the 45th American Society of Clinical Oncology Annual Meeting in Orlando, FL. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) The poster, entitled "Multi-Center Randomized Controlled Phase III Clinical Trial...

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) presented their data yesterday at the American Society of Clinical Oncology Annual Meeting."For this population with metastatic disease that cannot be cured by surgery, undergoing colon surgery is not always...

Novel chemotherapy and biological agents for metastatic colorectal cancer has resulted in increased patient survival, U.S. researchers say. Researchers at the University of Texas M.D. Anderson Cancer Center in Houston said researchers have made great strides in identifying active agents for the disease, resulting in U.S. Food and Drug Administration approval of numerous chemotherapeutic agents. The study, published in the Journal of Clinical Oncology, found that the median overall survival...

WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29, 2009 - June 2, 2009 in Orlando, FL. Senior clinical investigator, Neil N. Senzer, M.D., will present the data in an...

RESEARCH TRIANGLE PARK, N.C., May 14 /PRNewswire/ -- AlphaVax announced today the completion of enrollment in a Phase I/II CEA cancer immunotherapy study being conducted by the Duke University Comprehensive Cancer Center, Durham, NC. This Phase I/II study is an open-label, dose-escalation study to evaluate the safety and immunogenicity of carcinoembryonic antigen (CEA(6D))-expressing virus-like replicon particle (VRP) immunotherapy in patients with advanced or metastatic...

KVISTGARD, Denmark, May 9 /PRNewswire-FirstCall/ -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed. Instead of denying infringement, Oxford Biomedica made yet another attempt to dismiss the suit arguing that it was premature because TroVax(R) was still evaluated in clinical trials. The court ruled against Oxford Biomedica and the case will thus continue, based on the substance of the patents. Bavarian Nordic...